A yearslong U.S. Justice Department investigation into at least 12 pharmaceutical companies, including Israeli-based Teva Pharmaceutical Industries, has come to a head, with price collusion charges expected to emerge by year's end, according to a Bloomberg report. All 12 companies that have been named thus far have seen their stocks plummet, with Teva dropping by about 10% on the New York Stock Exchange Thursday, according to a Globes report. The companies are reportedly suspected of the price fixing several generic drugs. Some of the other pharmaceutical giants expected to face antitrust charges in the investigation are Mylan NV, Taro Pharmaceutical Industries and Impax Laboratories. Many of the companies have reportedly already disclosed receiving subpoenas and are cooperating with the investigation. Bloomberg quoted an email response to the reports from Teva spokeswoman Denise Bradley: "Teva is not aware of any facts that would give rise to an exposure to the company with respect to these subpoenas."
